Spruce Street Capital LP bought a new stake in Athira Pharma, Inc. (NASDAQ:ATHA – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 393,701 shares of the company’s stock, valued at approximately $2,980,000. Athira Pharma accounts for 1.0% of Spruce Street Capital LP’s investment portfolio, making the stock its 22nd biggest holding. Spruce Street Capital LP owned approximately 9.98% of Athira Pharma as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Jane Street Group LLC acquired a new position in Athira Pharma during the fourth quarter worth about $100,000. Renaissance Technologies LLC boosted its position in Athira Pharma by 44.7% during the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after acquiring an additional 23,223 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in Athira Pharma during the third quarter worth about $35,000. Institutional investors and hedge funds own 57.12% of the company’s stock.
Athira Pharma Trading Down 4.5%
ATHA opened at $8.22 on Tuesday. The firm has a market capitalization of $32.42 million, a PE ratio of -0.85 and a beta of 2.79. Athira Pharma, Inc. has a twelve month low of $0.23 and a twelve month high of $8.36. The firm’s 50-day moving average price is $9.51 and its 200 day moving average price is $7.36.
Athira Pharma Profile
Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).
The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.
Featured Articles
- Five stocks we like better than Athira Pharma
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
